Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Dec 15;110(13):4606-13.
doi: 10.1182/blood-2007-06-096966. Epub 2007 Sep 14.

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

Mohamed L Sorror  1 , Sergio Giralt, Brenda M Sandmaier, Marcos De Lima, Munir Shahjahan, David G Maloney, H Joachim Deeg, Frederick R Appelbaum, Barry Storer, Rainer Storb
Affiliations
Multicenter Study

Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences

Mohamed L Sorror et al. Blood. .

Abstract

A new hematopoietic cell transplantation-specific comorbidity index (HCT-CI) was effective in predicting outcomes among patients with hematologic malignancies who underwent HCT at Fred Hutchinson Cancer Research Center (FHCRC). Here, we compared the performance of the HCT-CI to 2 other indices and then tested its capacity to predict outcomes among 2 cohorts of patients diagnosed with a single disease entity, acute myeloid leukemia in first complete remission, who underwent transplantation at either FHCRC or M. D. Anderson Cancer Center (MDACC). FHCRC patients less frequently had unfavorable cytogenetics (15% versus 36%) and HCT-CI scores of 3 or more (21% versus 58%) compared with MDACC patients. We found that the HCT-CI had higher sensitivity and outcome predictability compared with the other indices among both cohorts. HCT-CI scores of 0, 1 to 2, and 3 or more predicted comparable nonrelapse mortality (NRM) among FHCRC and MDACC patients. In multivariate models, HCT-CI scores were associated with the highest hazard ratios (HRS) for NRM and survival among each cohort. The 2-year survival rates among FHCRC and MDACC patients were 71% versus 56%, respectively. After adjustment for risk factors, including HCT-CI scores, no difference in survival was detected (HR: 0.98, P = .94). The HCT-CI is a sensitive and informative tool for comparing trial results at different institutions. Inclusion of comorbidity data in HCT trials provides valuable, independent information.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The distribution of individual comorbidities. Individual comorbidities among (A) FHCRC and (B) MDACC patients as captured by each of the 3 indices, the HCT-CI, the ACE-27, and the CCI.
Figure 2
Figure 2
Cumulative incidences of NRM. Comparison of NRM among FHCRC and MDACC patients as stratified by HCT-CI scores of (A) 0, (B) 1 to 2, and (C) 3 or more. Solid lines represent FHCRC patients; dashed lines represent MDACC patients.
Figure 3
Figure 3
Kaplan-Meier curves for overall survival. OS as stratified by HCT-CI scores of 0, 1 to 2, and more than or equal to 3 among patients transplanted in (A) FHCRC and (B) MDACC.
Figure 4
Figure 4
Correlation between HCT-CI scores and age. Distribution of HCT-CI scores of 0, 1 to 2, and 3 or more among 4 age categories; less than 40, 40 to 49, 50 to 59, and more than 59 years of all patients (n = 224) with AML in first CR transplanted at FHCRC and MDACC. HCT-CI score 0, white area; HCT-CI scores 1 to 2, gray area; HCT-CI scores more than or equal to 3, black area.
See this image and copyright information in PMC

References

    1. Suciu S, Mandelli F, de Witte T, et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood. 2003;102:1232–1240. - PubMed
    1. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial: The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333. - PubMed
    1. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of pre-remission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96:4075–4083. - PubMed
    1. Ogawa H, Ikegame K, Kawakami M, et al. Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. Int J Hematol. 2004;79:495–500. - PubMed
    1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485. - PMC - PubMed

Publication types